melatonin and mdl 100907

melatonin has been researched along with mdl 100907 in 18 studies

Research

Studies (18)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	7 (38.89)	29.6817
2010's	11 (61.11)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chagraoui, A; Filloux, T; Mocaër, E; Protais, P	1
Lutterschmidt, DI; Mason, RT	1
Fuchs, E; Schmelting, B; Simon, M	1
Bertaina-Anglade, V; Boyer, PA; la Rochelle, CD; Mocaër, E	1
Arranz, B; San, L	1
Cardinali, DP; Hardeland, R; Pandi-Perumal, SR; Poeggeler, B; Spence, DW; Srinivasan, V; Trakht, I	1
Emsley, R; Goodwin, GM; Rembry, S; Rouillon, F	1
de Bodinat, C; Guardiola-Lemaitre, B; Millan, MJ; Mocaër, E; Muñoz, C; Renard, P	1
Bertaina-Anglade, V; Drieu-La-Rochelle, C; Mocaër, E; Seguin, L	1
Alvarez, JC; Barbot, F; Guilleminault, C; Hartley, S; Lofaso, F; Quera Salva, MA	1
Cranston, I; Dekeyne, A; Gabriel, C; Irons, JA; Millan, MJ; Mocaër, E; Norman, TR	1
Corbach-Söhle, S; Flügge, G; Fuchs, E; Kohlhause, S; Schlumbohm, C; Schmelting, B	1
Delmonte, D; Smeraldi, E	1
Blier, P; Chenu, F; El Mansari, M; Shim, S	1
Amore, M; Benassi, F; Cocito, L; Cordano, C; Emberti Gialloreti, L; Guida, S; Mattei, C; Pardini, M; Primavera, A; Sassos, D; Serrati, C	1
Noori, HR; Spanagel, R; Vengeliene, V	1
Bogdanovskaya, M; Cowen, PJ; Harmer, CJ; Pringle, A; Waskett, P; Zacharia, S	1
Amore, M; Benassi, F; Callegari, I; Cocito, L; Emberti Gialloreti, L; Grafman, J; Krueger, F; Massucco, D; Mattei, C; Nobili, F; Pardini, M; Sassos, D; Scialò, C; Serrati, C; Yaldizli, Ö	1

Reviews

6 review(s) available for melatonin and mdl 100907

Article	Year
Pharmacology of a new antidepressant: benefit of the implication of the melatonergic system. International clinical psychopharmacology, 2006, Volume: 21 Suppl 1 Topics: Acetamides; Animals; Antidepressive Agents; Biological Clocks; Brain; Depressive Disorder, Major; Disease Models, Animal; Drug Evaluation, Preclinical; Drugs, Investigational; Humans; Melatonin; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Receptor, Serotonin, 5-HT2C; Serotonin 5-HT2 Receptor Antagonists; Tupaiidae	2006
Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system. European psychiatry : the journal of the Association of European Psychiatrists, 2008, Volume: 23, Issue:6 Topics: Acetamides; Animals; Circadian Rhythm; Depressive Disorder, Major; Dopamine; Frontal Lobe; Humans; Hypnotics and Sedatives; Melatonin; Norepinephrine; Randomized Controlled Trials as Topic; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Serotonin 5-HT2 Receptor Antagonists	2008
The effect of melatonergic and non-melatonergic antidepressants on sleep: weighing the alternatives. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 2009, Volume: 10, Issue:4 Pt 2 Topics: Acetamides; Affect; Antidepressive Agents; Brain; Depressive Disorder, Major; Humans; Indenes; Melatonin; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Selective Serotonin Reuptake Inhibitors; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Sleep; Sleep Initiation and Maintenance Disorders	2009
Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nature reviews. Drug discovery, 2010, Volume: 9, Issue:8 Topics: Acetamides; Animals; Antidepressive Agents; Circadian Rhythm; Depressive Disorder, Major; Drug Design; Drug Discovery; Humans; Melatonin; Serotonin 5-HT2 Receptor Antagonists	2010
Circadian rhythms, melatonin and depression. Current pharmaceutical design, 2011, Volume: 17, Issue:15 Topics: Acetamides; Animals; Antidepressive Agents; Biological Clocks; Chronobiology Disorders; Depressive Disorder, Major; Humans; Melatonin; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Serotonin 5-HT2 Receptor Antagonists	2011
Agomelatine in depression. Expert opinion on drug safety, 2013, Volume: 12, Issue:6 Topics: Acetamides; Animals; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Humans; Melatonin; Serotonin 5-HT2 Receptor Antagonists; Treatment Outcome	2013

Trials

2 trial(s) available for melatonin and mdl 100907

Article	Year
Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial. The Journal of clinical psychiatry, 2009, Volume: 70, Issue:8 Topics: Acetamides; Adolescent; Adult; Aged; Depressive Disorder, Major; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hypnotics and Sedatives; Kaplan-Meier Estimate; Male; Melatonin; Middle Aged; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Secondary Prevention; Serotonin 5-HT2 Receptor Antagonists; Substance Withdrawal Syndrome; Treatment Outcome	2009
Agomelatine but not melatonin improves fatigue perception: a longitudinal proof-of-concept study. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2014, Volume: 24, Issue:6 Topics: Acetamides; Adult; Antidepressive Agents; Fatigue; Fatigue Syndrome, Chronic; Female; Follow-Up Studies; Humans; Longitudinal Studies; Male; Melatonin; Pilot Projects; Psychiatric Status Rating Scales; Quality of Life; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Receptor, Serotonin, 5-HT2C; Serotonin 5-HT2 Receptor Antagonists; Treatment Outcome	2014

Article

Year

Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial.

The Journal of clinical psychiatry, 2009, Volume: 70, Issue:8

Topics: Acetamides; Adolescent; Adult; Aged; Depressive Disorder, Major; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hypnotics and Sedatives; Kaplan-Meier Estimate; Male; Melatonin; Middle Aged; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Secondary Prevention; Serotonin 5-HT2 Receptor Antagonists; Substance Withdrawal Syndrome; Treatment Outcome

2009

Agomelatine but not melatonin improves fatigue perception: a longitudinal proof-of-concept study.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2014, Volume: 24, Issue:6

Topics: Acetamides; Adult; Antidepressive Agents; Fatigue; Fatigue Syndrome, Chronic; Female; Follow-Up Studies; Humans; Longitudinal Studies; Male; Melatonin; Pilot Projects; Psychiatric Status Rating Scales; Quality of Life; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Receptor, Serotonin, 5-HT2C; Serotonin 5-HT2 Receptor Antagonists; Treatment Outcome

2014

Other Studies

10 other study(ies) available for melatonin and mdl 100907

Article	Year
Agomelatine(S 20098) antagonizes the penile erections induced by the stimulation of 5-HT2C receptors in Wistar rats. Psychopharmacology, 2003, Volume: 170, Issue:1 Topics: Acetamides; Animals; Antidepressive Agents; Choroid Plexus; In Vitro Techniques; Indoles; Inositol Phosphates; Male; Melatonin; Naphthalenes; Penile Erection; Pizotyline; Pyridines; Rats; Rats, Wistar; Receptor, Serotonin, 5-HT2C; Receptors, Melatonin; Serotonin 5-HT2 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists; Swine	2003
A serotonin receptor antagonist, but not melatonin, modulates hormonal responses to capture stress in two populations of garter snakes (Thamnophis sirtalis parietalis and Thamnophis sirtalis concinnus). General and comparative endocrinology, 2005, May-01, Volume: 141, Issue:3 Topics: 5-Hydroxytryptophan; Adjuvants, Immunologic; Androgens; Animals; Colubridae; Corticosterone; Endocrine System; Ketanserin; Melatonin; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Stress, Physiological	2005
Antidepressant-like effects of agomelatine (S 20098) in the learned helplessness model. Behavioural pharmacology, 2006, Volume: 17, Issue:8 Topics: Acetamides; Aminopyridines; Animals; Antidepressive Agents; Avoidance Learning; Helplessness, Learned; Imipramine; Indoles; Male; Melatonin; Rats; Rats, Wistar; Receptors, Melatonin; Serotonin 5-HT2 Receptor Antagonists; Thiophenes	2006
Memory facilitating effects of agomelatine in the novel object recognition memory paradigm in the rat. Pharmacology, biochemistry, and behavior, 2011, Volume: 98, Issue:4 Topics: Acetamides; Aminopyridines; Animals; Antidepressive Agents; Drug Chronotherapy; Indoles; Male; Melatonin; Memory; Rats; Rats, Sprague-Dawley; Recognition, Psychology; Serotonin; Serotonin 5-HT2 Receptor Antagonists	2011
Agomelatine suppresses locomotor hyperactivity in olfactory bulbectomised rats: a comparison to melatonin and to the 5-HT(2c) antagonist, S32006. European journal of pharmacology, 2012, Jan-05, Volume: 674, Issue:1 Topics: Acetamides; Animals; Antidepressive Agents; Behavior, Animal; Hyperkinesis; Indoles; Male; Melatonin; Olfactory Bulb; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2C; Serotonin 5-HT2 Receptor Antagonists	2012
Agomelatine in the tree shrew model of depression: effects on stress-induced nocturnal hyperthermia and hormonal status. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2014, Volume: 24, Issue:3 Topics: Acetamides; Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Body Temperature; Body Weight; Central Nervous System Depressants; Circadian Rhythm; Depressive Disorder; Fever; Fluoxetine; Hydrocortisone; Indoles; Male; Melatonin; Motor Activity; Norepinephrine; Pyridines; Serotonin 5-HT2 Receptor Antagonists; Stress, Psychological; Tupaiidae	2014
Role of melatonin, serotonin 2B, and serotonin 2C receptors in modulating the firing activity of rat dopamine neurons. Journal of psychopharmacology (Oxford, England), 2014, Volume: 28, Issue:2 Topics: Aminopyridines; Animals; Dopaminergic Neurons; Indoles; Locus Coeruleus; Male; Melatonin; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2B; Receptor, Serotonin, 5-HT2C; Serotonin 5-HT2 Receptor Antagonists; Ventral Tegmental Area	2014
Activation of Melatonin Receptors Reduces Relapse-Like Alcohol Consumption. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2015, Volume: 40, Issue:13 Topics: Acetamides; Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Aminopyridines; Animals; Choice Behavior; Circadian Rhythm; Disease Models, Animal; Indoles; Male; Melatonin; Motor Activity; Rats, Wistar; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Recurrence; Serotonin 5-HT2 Receptor Antagonists	2015
Does melatonin treatment change emotional processing? Implications for understanding the antidepressant mechanism of agomelatine. Journal of psychopharmacology (Oxford, England), 2015, Volume: 29, Issue:10 Topics: Acetamides; Adolescent; Adult; Antidepressive Agents; Circadian Rhythm; Double-Blind Method; Emotions; Female; Healthy Volunteers; Humans; Male; Melatonin; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Receptor, Serotonin, 5-HT2C; Serotonin 5-HT2 Receptor Antagonists; Young Adult	2015
Agomelatine Improves Apathy in Frontotemporal Dementia. Neuro-degenerative diseases, 2016, Volume: 16, Issue:5-6 Topics: Acetamides; Antidepressive Agents; Apathy; Double-Blind Method; Female; Frontotemporal Dementia; Humans; Male; Melatonin; Middle Aged; Psychiatric Status Rating Scales; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Serotonin 5-HT2 Receptor Antagonists; Treatment Outcome	2016